Prognostic value of cartilage intermediate layer protein 1 in chronic heart failure
- PMID: 34939356
- PMCID: PMC8787959
- DOI: 10.1002/ehf2.13746
Prognostic value of cartilage intermediate layer protein 1 in chronic heart failure
Abstract
Aims: Emerging evidence suggests that cartilage intermediate layer protein 1 (CILP-1) is associated with myocardial remodelling. However, the prognostic value of circulating CILP-1 in patients with heart failure (HF) remains to be elucidated. This study aimed to investigate whether circulating CILP-1 can independently predict the outcome of chronic HF.
Methods and results: This prospective cohort study included 210 patients with chronic HF and left ventricular ejection fraction <50% between September 2018 and December 2019. The primary endpoint was 1 year all-cause mortality. During the 1 year follow-up, 28 patients died. In multivariable Cox proportional hazards regression analysis, higher CILP-1 levels were independently associated with a higher risk of mortality after adjusting for potential confounding factors. In Kaplan-Meier analysis, patients with CILP-1 levels above the median had a significantly higher mortality rate than those with CILP-1 levels below the median (log-rank P = 0.015). In addition, CILP-1 significantly improved prognostic prediction over N-terminal pro-brain natriuretic peptide by an increase in net reclassification improvement (P = 0.043) and a trend towards an increase in integrated discrimination improvement (P = 0.118).
Conclusions: Circulating CILP-1 is a novel independent prognostic predictor in chronic HF.
Keywords: Biomarker; CILP-1; Heart failure; Prognosis.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
None declared.
Figures
References
-
- Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland. Eur J Heart Fail 2017; 19: 1095–1104. - PubMed
-
- Tsuruha J, Masuko‐Hongo K, Kato T, Sakata M, Nakamura H, Nishioka K. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001; 44: 838–845. - PubMed
-
- Seki S, Tsumaki N, Motomura H, Nogami M, Kawaguchi Y, Hori T, Suzuki K, Yahara Y, Higashimoto M, Oya T, Ikegawa S, Kimura T. Cartilage intermediate layer protein promotes lumbar disc degeneration. Biochem Biophys Res Commun 2014; 446: 876–881. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
